New imaging method for study of insulin-producing cells in diabetes

A new imaging method for the study of insulin-producing cells in diabetes among other uses is now being presented by a group of researchers at Umeå University in Sweden in the form of a video in the biomedical video journal, The Journal of Visualized Experiments.

The developed techniques have contributed to the reasons why the research team recently received a SEK 4.3 million grant from the EU in a Marie Curie program to link together leading research teams in Europe in the field of diabetes imaging.

Professor Ulf Ahlgren and his associates at the Umeå Center for Molecular Medicine (UCMM) have subsequently elaborated the technology for biomedical imaging with optical projection tomography (OPT). Initially the method could only be used on relatively small preparations, but five years ago the scientists at Umeå were able to adapt the technology to study whole organs including the pancreas from adult mice. The present findings describe a further development of the OPT technology by going from ordinary visible light to the near-infrared spectrum. Near infrared light is light with longer wavelengths that can more easily penetrate tissue. Thereby, the developed imaging platform enables studies of considerably larger samples than was previously possible. This includes the rat pancreas, which is important because rats as laboratory animals are thought to be physiologically more similar to humans.

This adaptation, to be able to also image in near-infrared light, also means that the researchers gain access to a broader range of the light spectrum, making it possible to study more and different cell types in one organ preparation. In the article the scientists exemplify the possibility of simultaneously tracking the insulin-producing islets of Langerhans as well as the autoimmune infiltrating cells and the distribution of blood vessels in a model system for type-1 diabetes.

Internationally, huge resources are being committed to the development of non-invasive imaging methods for study of the number of remaining insulin cells in patients with developing diabetes. Such methods would be of great importance as only indirect methods for this exist today. However, a major problem in these research undertakings is to find suitable contrast agents that specifically bind to the insulin producing cells of the pancreas to allow imaging. In this context, the developed Near Infrared - OPT technology can play an important role as it enables the evaluation of new contrast agents. It may also be used as a tool to calibrate the non-invasive read out by e.g. magnetic resonance imaging (MRI). This is now going to be tested in the newly launched Marie Curie project "European Training Network for Excellence in Molecular Imaging in Diabetes," which links together five major EU-funded research consortia with different cutting-edge competences in the field.

The study by scientists from Umeå is presented in the Journal of Visualized Experiments, which is the first scientific journal to offer the video format for publication in the life sciences. Visualization in video presentations clearly facilitates the understanding and description of complex experimental technologies. It can help address two major challenges facing bioscience research: the low transparency and poor reproducibility of biological experiments and the large amounts of time and work needed to learn new experimental technologies.

Source: http://www.jove.com/video/50238/near-infrared-optical-projection-tomography-for-assessments-cell-mass

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes medication shows promise in reducing alcohol use